Lyten Acquires Europe’s Largest Battery Energy Storage Systems Manufacturing Operation from Northvolt
1.7.2025 09:00:00 CEST | Business Wire | Press Release
Lyten, the supermaterial applications company and global leader in lithium-sulfur batteries, announced today the acquisition of Northvolt’s Dwa ESS operations in Gdansk, Poland, a 25,000 square meter (270,000 sq ft) battery energy storage systems (BESS) manufacturing and R&D facility. Northvolt Dwa ESS is the largest BESS manufacturing facility in Europe and was part of Northvolt Systems. The financial terms of the acquisition are not being released by either party.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701098618/en/
Aerial view of the 25,000-square meter battery energy storage systems manufacturing facility, in Gdansk, Poland, acquired by Lyten from Northvolt. The facility, previously known as Northvolt Dwa ESS, is Europe’s largest energy storage systems manufacturing operation.
The Northvolt acquisition accelerates expansion of Lyten’s lithium-sulfur batteries into Europe and provides Lyten with production capacity to meet demand in the growing BESS market. Lyten has previously announced its lithium-sulfur batteries are shipping commercially for drones, launching onto the International Space Station, and selected by Chrysler, a Stellantis company, for its Halcyon Concept Electric Vehicle.
Lyten Lithium-Sulfur batteries have unique characteristics that make them ideally suited to meet rapidly growing demand for BESS: a broader operating temperature range especially in hot conditions, improved safety, and the ability to be made from abundantly available, low-cost materials found throughout the US and Europe. Lithium-Sulfur is also a high energy density, ultra-lightweight battery.
“Northvolt’s BESS manufacturing operations are truly world class and are a seamless strategic fit for Lyten as we launch an exciting new chapter for our company. We plan to immediately restart operations in Poland and deliver on existing and new customer orders,” said Dan Cook, Lyten CEO & Co-Founder. “The Port of Gdansk, local and federal officials have all been fully supportive as we combine Silicon Valley technology with Polish engineering and operations talent to export next generation energy storage technology to customers worldwide.”
The Dwa ESS facility came online in 2023. The facility includes equipment to ramp up to 6 GWh of energy storage manufacturing capacity and the footprint to expand to 10+ GWh in the future. The facility is supplied by renewable power and has contracted orders extending into 2026.
“The message we are hearing clearly from European customers is that they want energy storage systems manufactured in Europe using locally sourced supply chains free of geopolitical risk. Gdansk, Poland is the perfect location to meet this need for Europe,” added Lars Herlitz, Lyten Chairman and Co-Founder.
BESS is the fastest growing segment of the battery market, as the technology is critical to meet AI data center power demand, provide resiliency to the electricity grid in Europe and North America, and meet surging power demand in emerging markets. In December, Lyten announced a $650M LOI from the Export Import Bank of the US (EXIM) to expand battery manufacturing and commence delivery of BESS to Emerging Market nations.
Robert Chryc-Gawrychowski, CEO of Northvolt Poland, stated, “Northvolt set out to lead the sustainable development of Europe’s battery industry. Lyten is carrying that mission forward with BESS manufacturing and the introduction of lithium-sulfur batteries in Europe, which replaces minerals like nickel, cobalt, manganese, and graphite, with locally abundant battery materials. Moreover, it is important and exciting that the factory in Gdansk, built for the production of energy storage systems, will continue its operations.”
Aleksandra Dulkiewicz, President of Gdansk, stated, "The planned investment is a confirmation of the growing competitiveness of Poland and specifically Gdansk on the global economic map. For Gdansk, Lyten’s activities constitute an opportunity to cooperate in the field of energy storage, create energy innovation centres and advance R&D partnerships with local universities.”
In late 2024 Northvolt announced the intended sale of its Northvolt Systems business unit as part of its strategic review and bankruptcy procedures. Scania, a Swedish commercial vehicle manufacturer, announced the purchase of the Industrial subset of the Northvolt Systems division in April 2025.
Lyten and Northvolt intend to close the transaction in 3Q 2025.
About Lyten
Lyten, founded in 2015, is a supermaterial applications company that has received more than $425 million in equity investment and secured LOIs for $650M in financing from the Export Import Bank of the US. Lyten has built a proprietary materials platform, called Lyten 3D Graphene, that it uses to build better performing, lower cost, and decarbonizing products, including its next generation lithium-sulfur battery. Lyten corporate headquarters is in San Jose, CA and European headquarters is in Luxembourg.
The company lists more than 520 patents granted or pending and is currently manufacturing in San Jose, CA. Lyten recently announced the acquisition of Northvolt’s battery manufacturing plant in San Leandro, California to quickly scale production to meet the demand for American made batteries. In 2024, Lyten announced its integration into Chrysler’s Halcyon Concept electric vehicle, plans to integrate lithium-sulfur into AEVEX Aerospace’s unmanned aerial vehicles, and the selection of Lyten Lithium-Sulfur for demonstration on-orbit aboard the International Space Station (ISS), scheduled for launch later in 2025.
Lyten was named Fast Company’s #8 Most Innovative Energy Company and named one of America’s Top Green Technology Companies by Time in 2024 and one of the World’s Top Green Technology Companies by Time in 2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250701098618/en/
Contacts
Bob Zeitlinger
bzeitlinger@makovsky.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom